Celecoxib

Abstract

Each month, subscribers to The Formulary® Monograph Service receive five to six researched monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board called The Formulary Information Exchange (The F.I.X). All topics pertinent to clinical pharmacy are discussed on The F.I.X.

Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The May 1999 Formulary monographs are on pantoprazole, denileukin diftitox, nesiritide, sirolimus, and sodium ferric gluconate complex in sucrose. The DUE is on sodium ferric gluconate complex in sucrose.

Get full access to this article

View all access options for this article.

References

Anonymous. FDA approves Celebrex for arthritis. FDA Talk Paper. 1998(December 31); T98–89.

Celebrex package literature. Searle; December 1998.

Hebel

(ed). Drug Facts and Comparisons: Clinisphere Edition. St. Louis, MO: Facts and Comparisons; 1998.

Ladig

D.E.

Mosby's GenRx 1999: The Complete Reference for Generic and Brand Drugs. 9th ed. St. Louis, MO: Mosby; 1999.

Anderson

G.D.

Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest. 1996; 97: 2672–9.

Gierse

J.K.

A single amino acid difference between cyclooxygenase-1 (COX-1) and-2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J Biol Chem. 1996; 271: 15810–4.

Seibert

Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci. 1994; 91: 12013–7.

Portanova

J.P.

Selective neutralization of prostaglandin E₂ blocks inflammation, hyperalgesia, and interleukin 6 production in vivo. J Exp Med. 1996; 184: 883–91.

Needleman

, Isakson

P.C.

The discovery and function of COX-2. J Rheumatol. 1997; 24(suppl 49): 6–8.

10.

Lipsky

P.E.

, Isakson

P.C.

Outcome of specific COX-2 inhibition in rheumatoid arthritis. J Rheumatol. 1997; 24(suppl 49): 9–14.

11.

Peskar

B.M.

, Maricic

Role of prostaglandins in gastroprotection. Dig Dis Sci. 1998; 43(suppl): 235–95.

12.

Kurumabail

R.G.

Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature. 1996; 384: 644–8.

13.

Cannon

MK-0966, a specific COX-2 inhibitor, has clinical efficacy comparable to diclofenac in the treatment of knee and hip osteoarthritis (OA) in a 26-week controlled clinical trial. American College of Rheumatology 62nd National Meeting [abstracts]. San Diego, CA; November 8-12, 1998: 983.

14.

Crofford

L.J.

COX-1 and COX-2 tissue expression: Implications and predictions. J Rheumatol. 1997; 24(suppl 49): 15–9.

15.

Lane

N.E.

Pain management in osteoarthritis: The role of COX-2 inhibitors. J Rheumatol. 1997; 24(suppl 49): 20–4.

16.

Kawamori

Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon car-cinogenesis. Cancer Res. 1998; 58: 409–12.

17.

Ziegler

Cancer and arthritis share underlying processes. J Natl Cancer Inst. 1998; 90(11): 802–3.

18.

Simon

L.S.

Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum. 1998; 41: 1591–1602.

19.

Riendeau

Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays. Can J Physiol Pharmacol. 1997; 75: 1088–95.

20.

Hubbard

Efficacy, tolerability, and safety of celecoxib, a specific COX-2 inhibitor, in osteoarthritis [abstract]. Arthritis Rheum. 1998; 41(9 suppl): S196: 982.

21.

Saag

MK-0966, a specific COX-2 inhibitor, has clinical efficacy comparable to ibuprofen in the treatment of knee and hip osteoarthritis (OA) in a 6-week controlled clinical trial. American College of Rheumatology 62nd National Meeting [abstracts]. San Diego, CA; November 8-12, 1998: 984.

22.

Geis

G.S.

Safety and efficacy of celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis. Arthritis Rheum. 1998; 41(9 suppl): S364: 1990.

23.

Geis

G.S.

Efficacy and safety of celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis. Arthritis Rheum. 1998; 41(9 suppl): S316: 1699.

24.

Lanza

Selective inhibition of cyclooxygenase-2 (COX-2) with MK-0966 (250 mg Q.D.) is associated with less gastroduodenal damage than aspirin (ASA) 650 mg Q.I.D. or ibuprofen (IBU) 800 mg T.I.D. [abstract]. Gastroenterol. 1998; 112: A194.

25.

Singh

Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med. 1998; 105(1B): 31S–8S.

26.

Anonymous. Monsanto painkiller approved: Label to bear warning. Washington, DC: Bloomberg; December 31,1998.

27.

Karim

Celecoxib, a specific COX-2 inhibitor, lacks significant drug-drug interactions with methotrexate or warfarin. Arthritis Rheum. 1998; 41(9 suppl): S315: 1698.

28.

Tatro

D.S.

(ed). Drug Interaction Facts. St. Louis, MO: Facts and Comparisons; 1998.

29.

Hansten

P.D.

, Horn

Drug Interactions Analysis and Management. Vancouver, WA: Applied Therapeutics, Inc.; 1998.

30.

Anonymous. Merck files osteoarthritis drug application. Reuters; November 23, 1998. www.reutershealth.com

31.

Anonymous. FDA grants priority review for Vioxx, Merck's investigational medicine for osteoarthritis and pain. PRNewswire. January 11, 1999. www.prnewswire.com